Seeking Alpha
19 Aug 2026, 14:52 UTC · 1h ago
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
19 Aug 2026, 14:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Eyepoint Pharmaceuticals' LUGANO Phase 3 trial for Duravyu in wet AMD failed to meet its primary endpoint. — The failure of a pivotal Phase 3 trial for a lead candidate typically results in severe valuation loss, as evidenced by the 70% stock price crash.
-0.90Data from the LUCIA Phase 3 study is expected in Q4 2026. — This represents the primary remaining catalyst that could either validate the drug's efficacy or confirm the program's failure.
+0.50Company management claims the LUGANO failure was caused by an anomalous cohort of nine patients with unrelated vision loss. — While providing a theoretical path to recovery, management explanations for failed trials are often viewed with skepticism by the market.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The stock crashed ~70% following a Phase 3 trial failure, although the author views it as a speculative buy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
5h ago
